NCT03828058View on ClinicalTrials.gov

Envarsus XL Immunosuppression Following Liver Transplantation

PHASE2CompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

April 1, 2019

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2020

Conditions
Recipients of Liver Transplant
Interventions
DRUG

Envarsus XR

Envarsus XR to be administered orally, once a day. Dosage will be adjusted as determined by trough blood levels.

DRUG

Prograf

Prograf 2 mg BID to be administered orally, twice a day. Dosage will be adjusted as determined by trough blood levels.

Trial Locations (1)

38104

Methodist Healthcare, University Hospital, Memphis

Sponsors
All Listed Sponsors
lead

Methodist Healthcare

OTHER

NCT03828058 - Envarsus XL Immunosuppression Following Liver Transplantation | Biotech Hunter | Biotech Hunter